Lacouture Mario E, Cotliar Jonathan, Mitchell Edith P
Department of Dermatology, Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):17-21.
Management of dermatologic toxicities from epidermal growth-factor receptor inhibitors (EGFRIs) is best tailored to the type of skin lesions present, extent of body surface involvement, and anatomic location affected. Although few randomized trials have been undertaken to address treatment of skin, hair, or nail side effects to this class of drugs, some basic principles of therapy based on experience of referral centers can help mitigate these toxicities and ensure consistent EGFRI administration and maintenance of patient quality of life. Patient education as to the expected EGFRI side effects and early physician intervention when these side effects appear can improve outcomes. Two dermatologists who treat high numbers of patients affected by these EGFRI-induced cutaneous side effects submit their recommendations for management.
表皮生长因子受体抑制剂（EGFRIs）所致皮肤毒性的管理，最好根据出现的皮肤病变类型、体表面积受累范围以及受影响的解剖部位进行调整。尽管针对这类药物的皮肤、毛发或指甲副作用的治疗，几乎没有进行过随机试验，但基于转诊中心的经验，一些基本治疗原则有助于减轻这些毒性，并确保EGFRIs的持续给药以及患者生活质量的维持。对患者进行关于预期EGFRIs副作用的教育，以及在这些副作用出现时医生的早期干预，可以改善治疗效果。两位治疗大量受这些EGFRIs引起的皮肤副作用影响患者的皮肤科医生提交了他们的管理建议。
